Investigational drug · Phase 3
Povetacicept
Also called: ALPN-303
Not approved by FDA. In 7 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Immunoglobulin A Nephropathy, Myasthenia Gravis, Generalized, Primary Membranous Nephropathy.
Phase 3Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
7
6 still active
All registered trials
8
Any phase or sponsor naming "Povetacicept"
First trial start
2023
Mar 15, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Povetacicept", any sponsor or status.
Conditions studied
As listed on its trial records.
- Immunoglobulin A Nephropathy
- Myasthenia Gravis, Generalized
- Primary Membranous Nephropathy
- Lupus Nephritis
- Membranous Nephropathy
- Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
- Idiopathic Thrombocytopenic Purpura
- Immune Thrombocytopenia
- Warm Autoimmune Hemolytic Anemia
- Cold Agglutinin Disease
Approved drugs for the same conditions: Anemia · Immune thrombocytopenia · Myasthenia gravis · Lupus (SLE) · IgA nephropathy · Hematology and blood cancers · Cardiovascular and metabolic · Neurology · Immunology and inflammation · Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "Povetacicept" as an intervention, largest first.
- Evaluation of Efficacy of Povetacicept in Adults With Immunoglobulin A Nephropathy (IgAN)Pivotal-lookingActive, not recruiting
Alpine Immune Sciences Inc, A Subsidiary of VertexIndustry
NCT06564142 · 605 participants · Start Aug 30, 2024 · Primary completion Jan 30, 2028
Drug: Povetacicept; Placebo (matched to Povetacicept) · For: Immunoglobulin A Nephropathy
Sites: Huntsville, Alabama; Phoenix, Arizona; Tucson, Arizona · 318 sites in all
- A Phase 3 Open-Label Study of Long-term Treatment With Povetacicept in Adults With Immunoglobulin A NephropathyPivotal-lookingEnrolling by invitation
Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
NCT07807995 · 605 participants (planned) · Start Sep 17, 2026 · Primary completion Dec 28, 2029
Drug: Povetacicept · For: Immunoglobulin A Nephropathy
Sites: Arvada, Colorado; Orlando, Florida; Idaho Falls, Idaho · 4 sites in all
- Evaluation of Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropathy (pMN)Pivotal-lookingRecruiting
Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
NCT07204275 · 176 participants (planned) · Start Sep 30, 2025 · Primary completion Jun 27, 2029
Drug: Povetacicept; Tacrolimus · For: Primary Membranous Nephropathy
Sites: Montgomery, Alabama; Surprise, Arizona; Los Angeles, California · 119 sites in all
- A Study to Evaluate the Relative Bioavailability of Povetacicept Formulations and Bioequivalence of Povetacicept PresentationsPivotal-lookingCompleted
Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
NCT07010406 · 136 participants · Start Jun 6, 2025 · Primary completion Aug 19, 2025
Drug: Povetacicept · For: Healthy Volunteers
Sites: Tempe, Arizona; Lincoln, Nebraska
- An Open-label Study of Povetacicept in Autoantibody-Associated Glomerular DiseasesActive, not recruiting
Alpine Immune Sciences, Inc.Industry
NCT05732402 · 72 participants · Start Mar 15, 2023 · Primary completion Mar 2, 2028
Drug: Povetacicept · For: Lupus Nephritis; Immunoglobulin A Nephropathy; Membranous Nephropathy and 1 more
Sites: Phoenix, Arizona; Tucson, Arizona; Valencia, California · 30 sites in all
- A Phase 3b Study of Participant Experience on Povetacicept Administered Via Autoinjector as Compared to Sibeprenlimab Administered Via Prefilled SyringePivotal-lookingRecruiting
Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
NCT07890909 · 40 participants (planned) · Start Nov 13, 2026 · Primary completion Dec 12, 2027
Drug: Povetacicept; Sibeprenlimab · For: Immunoglobulin A Nephropathy
Sites: Orlando, Florida; Lawrenceville, Georgia
- A Phase 2 Study to Evaluate Povetacicept in Adults With Generalized Myasthenia GravisActive, not recruiting
Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
NCT07501702 · 34 participants · Start May 13, 2026 · Primary completion Mar 2, 2029
Drug: Povetacicept; Placebo · For: Myasthenia Gravis, Generalized
Sites: Mission Hills, California; Boca Raton, Florida; Homestead, Florida · 31 sites in all
Alpine Immune Sciences Inc, A Subsidiary of VertexIndustry
NCT05757570 · 30 participants · Start Jul 3, 2023 · Primary completion Aug 12, 2026
Drug: Povetacicept · For: Idiopathic Thrombocytopenic Purpura; Immune Thrombocytopenia; Warm Autoimmune Hemolytic Anemia and 1 more
Sites: Los Angeles, California; Washington D.C., District of Columbia; Cooper City, Florida · 44 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Interim Analysis of a Phase 3 Trial of Povetacicept in IgA Nephropathy.
Barratt J, Zhang H, Han SH, et al. · N Engl J Med 2026
- Targeting the B-Cell Activating Factor and a Proliferation-Inducing Ligand Pathway in IgAN: From Disease Pathogenesis to Clinical Trial Evidence.
Vasquez-Rios G, Rajasekaran A, Coca SG, et al. · Kidney Int Rep 2026
- Atacicept in IgA nephropathy.
Doggrell SA · Expert Rev Clin Immunol 2026
- Correction to "Povetacicept, an Enhanced Dual APRIL/BAFF Antagonist That Modulates B Lymphocytes and Pathogenic Autoantibodies for the Treatment of Lupus and Other B Cell-Related Autoimmune Diseases".
· Arthritis Rheumatol 2026
- Povetacicept for IgA Nephropathy and Primary Membranous Nephropathy.
Madan A, Yalavarthy R, Kim DK, et al. · Kidney Int Rep 2026
- Emerging Therapies in IgA Nephropathy: From A Proliferation-Inducing Ligand (APRIL) and B-cell Activating Factor (BAFF) Inhibitors to Precision Medicine.
Sharma I, Panta R · Cureus 2025
Also in development for Immunoglobulin A Nephropathy
- FelzartamabPhase 38 trials
Biogen · Antibody-mediated Rejection, Microvascular Inflammation, Graves' Disease
- FUB523zigakibart, BION-1301Phase 36 trials
Novartis · IgA Nephropathy, Immunoglobulin A Nephropathy, IgA Nephropathy (IgAN)
- matched to PovetaciceptPhase 31 trial
Alpine Immune Sciences Inc, A Subsidiary of Vertex · Immunoglobulin A Nephropathy
- MIL116Phase 21 trial
Beijing Mabworks Biotech Co., Ltd. · Immunoglobulin A Nephropathy
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Vertex Pharmaceuticals.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.